References
- Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–20. doi:https://doi.org/10.1016/S0140-6736(07)60983-0.
- Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors’ progress along an extra-adrenal chromaffin lineage. Lab Invest. 1996;75(5):659–75.
- Koufopoulos N, Kokkali S, Manatakis D, Balalis D, Nasi D, Ardavanis A, Korkolis D, Khaldi L. Primary peripheral neuroectodermal tumor (PNET) of the adrenal gland: a rare entity. J Buon. 2019 Mar–Apr; 24(2):770–8.
- Huh J, Kim KW, Park SJ, Kim HJ, Lee JS, Ha HK, Tirumani SH, Ramaiya NH. Imaging features of primary tumors and metastatic patterns of the extraskeletal Ewing sarcoma family of tumors in adults: a 17-year experience at a single institution. Korean J Radiol. 2015;16(4):783–90. doi:https://doi.org/10.3348/kjr.2015.16.4.783.
- Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4(11):1342–53. doi:https://doi.org/10.1158/2159-8290.CD-14-0622.
- Toraih EA, Toreih AA, Fawzy MS. Catching the driver mutations in Ewing sarcoma tumours: an in silico genomic analysis. WCRJ. 2019;6:e1321.
- Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017;16(1):114. doi:https://doi.org/10.1186/s12943-017-0686-8.
- Chisholm KM, Krishnan C, Heerema-McKenney A, Natkunam Y. Immunohistochemical profile of MYC protein in pediatric small round blue cell tumors. Pediatr Dev Pathol. 2017; 20(3):213–23. doi:https://doi.org/10.1177/1093526616689642.
- Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H. MicroRNA-20b promotes cell proliferation via targeting of TGF-β receptor II and upregulates MYC expression in Ewing’s sarcoma cells. Int J Oncol. 2017;51(6):1842–50. doi:https://doi.org/10.3892/ijo.2017.4155.
- Fizazi K, Le Cesne A, Dohollou N, Affaied S, Spielmann M, Le Chevalier T. Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing’s sarcoma family of tumours. Eur J Cancer. 1996;32 (10):1823–4. doi:https://doi.org/10.1016/0959-8049(96)00165-7.
- Desai SS, Jambhekar NA. Pathology of Ewing’s sarcoma/PNET: Current opinion and emerging concepts. Indian J Orthop. 2010;44(4):363–8. doi:https://doi.org/10.4103/0019-5413.69304.
- Karadurmus N, Sahin U, Bahadir Basgoz B, Demirer T. Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing’s sarcoma and osteosarcomas? J Buon. 2018; 23(5):1235–41.
- Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C. High-risk neuroblastoma treatment strategy: the experience of the SIOPEN group. Bull Cancer. 2018;105(10):918–24. doi:https://doi.org/10.1016/j.bulcan.2018.09.002.